A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AJ302-IM in Healthy Volunteers
A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of AJ302-IM in Healthy Volunteers Via Intramuscular Injection
Sponsor: AnnJi Pharmaceutical Co., Ltd.
Listed as NCT06625541, this PHASE1 trial focuses on Healthy Volunteers and remains completed. Sponsored by AnnJi Pharmaceutical Co., Ltd., it has been updated 2 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
2 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Nov 2024 — Jan 2026 [monthly]
Recruiting PHASE1
First recorded
Jun 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AnnJi Pharmaceutical Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .